COZADD BRUCE C 4
4 · Jazz Pharmaceuticals plc · Filed Nov 20, 2025
Insider Transaction Report
Form 4
COZADD BRUCE C
Director
Transactions
- Sale
Ordinary Shares
2025-11-18$180.88/sh−8,382$1,516,131→ 397,060 total - Sale
Ordinary Shares
2025-11-18$181.81/sh−5,517$1,003,071→ 391,543 total - Sale
Ordinary Shares
2025-11-18$180.09/sh−3,384$609,411→ 405,442 total - Award
Ordinary Shares
2025-11-20+2,506→ 393,332 total - Sale
Ordinary Shares
2025-11-18$182.60/sh−717$130,925→ 390,826 total
Footnotes (5)
- [F1]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.4013 to $180.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $180.4028 to $181.385. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $181.41 to $182.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F4]Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $181.59 to $182.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F5]These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.